| 000 | 01521 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250514051928.0 | ||
| 264 | 0 | _c20030213 | |
| 008 | 200302s 0 0 eng d | ||
| 022 | _a1079-2082 | ||
| 024 | 7 |
_a10.1093/ajhp/59.21.2078 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBrown, Philip M | |
| 245 | 0 | 0 |
_aLack of pharmacokinetic interactions between argatroban and warfarin. _h[electronic resource] |
| 260 |
_bAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists _cNov 2002 |
||
| 300 |
_a2078-83 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 |
_aAnticoagulants _xadverse effects |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aArginine _xanalogs & derivatives |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPipecolic Acids _xadverse effects |
| 650 | 0 | 4 | _aSulfonamides |
| 650 | 0 | 4 |
_aWarfarin _xadverse effects |
| 700 | 1 | _aHursting, Marcie J | |
| 773 | 0 |
_tAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists _gvol. 59 _gno. 21 _gp. 2078-83 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/ajhp/59.21.2078 _zAvailable from publisher's website |
| 999 |
_c12241637 _d12241637 |
||